Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NDO Surgical has reported that the results of a five-year follow up study of its Plicator anti-reflux surgery device and procedure demonstrated long term durability of the procedure as well as sustained quality of life improvement and reduced dependency on medication therapy for gastroesophageal reflux disease patients.
Subscribe to our email newsletter
At five-years post procedure, 67% of patients who required daily PPI’s prior to receiving Plicator treatment remained off daily PPI therapy and gastroesophageal reflux disease (GERD) HRQL scores remained significantly improved (10 versus 19 p< 0.001). In addition, 50% of patients experienced a greater than 50% improvement in their GERD HRQL scores while also experiencing no late occurring adverse events. Plicator therapeutic response at 5-years post-treatment was comparable to the outcomes observed at 3-years post-treatment, demonstrating stable reconstructive efficacy. Bernard Haffey, president and CEO of NDO, said: "Plicator is the most studied, most advanced endoluminal surgical device and procedure available to GERD patients and can be a long term alternative to daily PPI therapy."